“Positive Contrast” Inversion-Recovery With Oxide Nanoparticles-Resonant Water Suppression Magnetic Resonance Imaging A Change for the Better?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. by Lipinski, Michael J. et al.
“
I
O
W
R
A
M
K
V
Z
C
T
l
m
t
l
r
t
h
c
m
e
p
c
o
u
a
l
i
w
p
s
e
c
r
w
s
o
i
d
M
m
t
n
a
o
a
m
m

t
c
m
h
d
(
e
a
c
a
w
c
n
b
p
o
t
i
s
u
n
s
s
a
i
r
i
a
*
v
A
S
m
M
M
p
B
F
Journal of the American College of Cardiology Vol. 52, No. 6, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2008.03.062EDITORIAL COMMENT
Positive Contrast”
nversion-Recovery With
xide Nanoparticles-Resonant
ater Suppression Magnetic
esonance Imaging
Change for the Better?*
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harlottesville, Virginia; and New York, New York
he identification and characterization of atherosclerotic
esions prone to rupture in asymptomatic individuals re-
ains a major focus of diagnostic imaging research. Al-
hough ischemic events often result from severely stenotic
esions in the peripheral arteries, the majority of atheroscle-
otic lesions responsible for acute coronary syndromes are
ypically 50% stenosed prior to the event (1,2). Studies
See page 483
ave clearly shown that vulnerability is dependent on plaque
omposition, with most vulnerable plaques exhibiting high
acrophage density, lipid rich cores, necrosis, and the
stablishment of plaque neovasculature (3). This may ex-
lain why over one-half of individuals present with myo-
ardial infarction or sudden death as their first manifestation
f atherosclerosis (4). Development of noninvasive molec-
lar imaging probes that target components of vulnerable
therosclerotic plaque may enable improved detection of
esions prone to rupture and may allow for early therapeutic
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ent of Radiology, the Zena and Michael A. Wiener Cardiovascular Institute, the
arie-Josée and Henry R. Kravis Cardiovascular Health Center, and Department of
edicine, Mount Sinai School of Medicine, New York, New York. This work was
artly funded by the National Institutes of Health and the National Heart, Lung, andt
lood Institute (NIH/NHLBI ROI HL71021, NIH/NHLBIHL78667) (to Dr.
ayad) and the Heritage affiliate of the American Heart Association (to Dr. Mani).ntervention (5). However, this raises the larger question of
hether imaging can provide information in addition to
roven clinical risk factors that may alter therapy other than
imply initiating cardioprotective medications.
High-resolution magnetic resonance imaging (MRI) has
merged as a leading noninvasive imaging modality for
haracterizing atherosclerotic plaque in vivo (6). Magnetic
esonance imaging provides high-spatial-resolution images
ithout the need for ionizing radiation and can be repeated
equentially over time to monitor therapeutic intervention
r assess plaque progression and regression. Due to the
mportance of macrophages in plaque progression and
estabilization, several paramagnetic and superparamagnetic
RI agents have been developed to specifically image the
acrophage burden in atherosclerotic plaque (7,8). Al-
hough macrophage targeting using gadolinium-based
anoparticles appears promising (9), the safety of these
gents has yet to be established. Iron oxide particles, on the
ther hand, have long been used clinically to target cells
ssociated with both the reticular endothelial system and
onophagocytic system (10).
Iron oxide particles range in size from ultrasmall superpara-
agnetic particles of iron oxide (SPIO) with a diameter of
20 nm to SPIO with a diameter of 100 nm to micropar-
icles of iron oxide with a diameter of 1 m. These particles
onsist of an iron oxide core(s) and sometimes a coating
aterial such as dextran. Cross-linked iron oxide nanoparticles
ave also been modified with other imaging probes to generate
ual-imaging agents that enable both magnetic resonance
MR) and optical in vivo imaging of specific targets or cellular
nzymatic activity (11). Low toxicity, commercial availability,
nd the ability to modify particle size and coating (affecting
irculation time, cellular uptake, and plaque penetration) are
dvantages of these contrast agents. Generally, for particles
ith similar coating, uptake and therefore MR efficacy in-
reases as the particle size decreases (12).
The contrast agents appear to be phagocytosed by mono-
uclear cells, enabling quantification of resident macrophage
urden and the degree of inflammation in atherosclerotic
laque (13). Internalization and compartmentalization of iron
xide particles within macrophages causes MR signal loss due
o the generation of local magnetic field inhomogeneities that
nduce T2/T2* effects (14). Typically, T2 and/or T2*-weighted
equences are used to observe the signal loss generated after the
ptake of the iron oxide particles within the cells. Iron oxide
anoparticles can also be modified with antibodies to image
pecific ligands in atherosclerotic plaques (15). In vivo MRI of
tem cell (16) or inflammatory cell (17) trafficking has also been
chieved by extracting the cells of interest and “loading” them with
ron oxide particles to characterize their migration into atheroscle-
otic lesions or their role in other disease processes. Figure 1
llustrates different strategies of identifying atherosclerotic plaque
nd degree of inflammation using iron oxide particles.
However, interpretation of the signal loss generated by
he particles may be challenging due to issues associated
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August 5, 2008:492–4 Editorial Commentith partial voluming, perivascular effects, and other sus-
eptibility artifacts. It is often challenging to distinguish the
ignal void generated by the contrast agents from motion or
ow artifacts and inherent T2* effects in the plaque. Signal
oss is also heavily dependent on image resolution and
egional contrast agent concentration. To overcome these
imitations, several groups have developed “positive” con-
rast imaging sequences as an alternative means of detecting
ron oxide particles with MRI (18–21). These positive
ontrast sequences allow for the generation of positive MR
ignal in volumes or regions containing iron particles. The
urrent positive contrast sequences are classified as: off-
esonance methods that shift the excitation frequency to
atch the frequency shift caused by the iron particles (19);
elective RF pulse methods, such as the inversion-recovery
ith oxide nanoparticles–resonant water suppression
IRON) sequence, that selectively excite regions containing
ron particles (21); dephased methods that use either the
hift in k space caused by the presence of iron particles or
ephased areas where particles are present (18,20); and
ltrashort echo time methods. The utility of the individual
Figure 1 3 Imaging Strategies Using Iron Oxide Nanoparticles
An illustration of 3 strategies using iron oxide nanoparticles (A) for imaging the ca
resonant water repression magnetic resonance imaging (MRI). Iron oxide particles
(arrows) pass through the endothelium (H), fibrous cap (I), and are taken up by r
with and take up iron oxide particles (C). The cells can then be injected intravenou
be used to detect stem cells loaded with iron oxide particles (arrows) that migrate
to antibodies that specifically target components of atherosclerotic plaque (D). As
endothelial cells (H) with iron oxide particles attached to antibodies targeting vascositive contrast methods may be application-dependent, iecause the sensitivity will depend on the compartmental-
zation and magnetic field distribution of the iron particles
22). As a result, some techniques may be better at detecting
ow concentrations of highly compartmentalized iron
dephasing methods), and others may be more sensitive for
etecting larger field distributions. Currently a single study
hat compares the various methodology of detection of iron
n macrophages is lacking in the literature.
In this issue of the Journal, Korosoglou et al. (23) present
heir study using IRON MRI with monocrystalline iron
xide nanoparticles (MION)-47 to detect macrophage-rich
therosclerotic plaque in a rabbit model of atherosclerosis.
he investigators previously employed IRON MRI for in
ivo positive contrast imaging of SPIO-loaded stem cells to
ocalize the cells following injection on post-contrast imag-
ng (21). In this study, pre-contrast imaging was performed
n 7 Watanabe rabbits and 4 control New Zealand rabbits.
commercially available iron oxide contrast agent, MION-
7, was then injected intravenously and post-contrast im-
ging was repeated on days 1 and 3. A second injection was
erformed on day 3 following imaging and post-contrast
scular system with positive contrast inversion-recovery with oxide nanoparticles–
(B) can be injected intravenously and, as seen in panel E, iron oxide particles
t macrophages in the lipid core (J). Alternatively, stem cells can be incubated
d cellular migration can be determined with MRI. As seen in panel F, MRI may
region of myocardial infarction. Finally, iron oxide nanoparticles can be attached
in panel G, MRI can be used to detect integrins expressed on the surface of
ell adhesion molecule-1 or other integrins (arrows).rdiova
alone
esiden
sly an
to a
seen
ular cmaging was again performed on day 6. There was a significant
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Editorial Comment August 5, 2008:492–4ncrease in signal intensity in aortic atherosclerotic plaque
ollowing administration of MION-47 (48% increase on day 3
nd 72% increase on day 6), but no enhancement was seen in
ontrol rabbits that lack atherosclerosis. Additionally, posi-
ive contrast corresponded to the deposition of super-
aramagnetic nanoparticles in macrophage-rich atheroscle-
otic plaques. These findings are significant as they not only
alidate MION-47 as a successful imaging agent for
acrophage-rich atherosclerosis, but also suggest that pos-
tive contrast IRON MRI can be applied to the general class
f iron oxide particles. This is significant as iron oxide–
ased contrast agents have been previously studied in
umans (13), enabling IRON MRI sequences to be directly
pplied to patient care. Comparison between previous find-
ngs using T2- and T2*-weighted imaging with positive
ontrast protocols will now be necessary to validate that
reviously used doses of ultrasmall SPIO will be adequate
or detection of atherosclerosis. However, because both
ethods use the same local magnetic field inhomogeneities
o produce MR signal gain (off-resonance signal by IRON)
r signal loss (dephasing by conventional gradient echo
maging), the correlations are expected to be similar. The
pecificity of the IRON technique to macrophages loaded
ith iron oxides needs to be established. This is critical
ecause positive enhancement is observed in other regions
utside of the arterial vessel wall. The positive contrast in these
egions appears to occur at membrane interfaces and areas that
ay experience other sources of field inhomogeneities.
Though the findings of this report have many exciting
mplications for the field of MRI, it is important to recognize
everal limitations of this study. First, the amount of
ION-47 used in this study was 10 times above the recom-
ended clinical dosing. Additionally, to increase intraplaque
acrophage uptake (saturation of the reticular endothelial
ystem), the investigators employed 2 separate administrations
f MION-47. Even though the rabbit aorta is similar in size to
uman coronary arteries, several limitations remain in human
oronary imaging, including image resolution and the need for
reath holding and electrocardiographic gating.
Despite these limitations, we eagerly look forward to the
ontinued application of IRON MRI and other positive
ontrast imaging sequences for the evaluation of macrophage-
ich human atherosclerosis.
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